Data Demonstrating vMap’s Impact on Atrial Fibrillation Treatment Outcomes Unveiled at AF Symposium 2024
01 Feb 2024
Clinical Result
BOSTON--(BUSINESS WIRE)--Vektor Medical, a pioneer in non-invasive arrhythmia analysis technology, will release findings today at AF Symposium from the recent study Ablation of Non-Pulmonary Vein Atrial Fibrillation Drivers Identified by Machine Learning in Addition to Pulmonary Vein Isolation Improves Procedural Outcomes. Additionally, Dr. Jag Singh, a world-renowned expert in artificial intelligence, medical sensors, and the future of healthcare, will present on vMap as part of the Symposium’s Spotlight Sessions.
Data: vMap's Impact on AF Treatment Outcomes
The study demonstrates how non-pulmonary vein AF driver ablation guided by vMap could improve ablation outcomes for patients with persistent AF, recurrent AF after prior ablation, or AF associated with atrial flutter or focal AT.
Key Data Points:
All patients in the study group (n=27) and controls (n=54) underwent standard-of-care pulmonary vein isolation (PVI).
Following PVI, the study group (n=27) had ablation of 1.6 ± 0.7 additional AF driver sites identified by vMap’s artificial intelligence-based analysis.
During ablation, 15 patients in the study group had driver site ablation during ongoing AF or focal AT resulting in atrial termination in 80% of such cases.
86.5% of patients in the vMap study group were free from AF and AT on or off antiarrhythmic medications at 1-year follow-up, compared to 48.0% of the control group.
Dr. Jag Singh’s Spotlight Session
Dr. Singh will discuss the transformative potential of vMap and its AI-powered algorithms. He will share how these innovations enhance physicians’ ability to treat cardiac arrhythmias more accurately and efficiently while spearheading healthcare through digital innovation.
Details:
Saturday, February 3
1:30—2:30 PM ET
Spotlight Session II: Unlocking Arrhythmias: vMap's AI-Driven Revolution
“The AF Symposium provides us with a distinctive opportunity to share new data and evidence demonstrating how vMap is moving cardiac care forward for patients and unlocking valuable insights for physicians,” said Rob Krummen, CEO of Vektor Medical. “With four-chamber mapping that is both intuitive and accurate, vMap is leading the way in improving ablation outcomes for patients, optimizing workflows for providers, and increasing procedural efficiency for physicians.”
Attendees are invited to visit the Vektor booth (#300) at AF Symposium to experience vMap, the novel technology revolutionizing arrhythmia care.
About vMap®
vMap is the only FDA-cleared, non-invasive AI-based solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillation-type arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-based, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com.
Follow Vektor Medical: LinkedIn and Twitter/X.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.